Payment overview · 2025
General Payments
$183.58
9 reported records · 6 companies
Healthcare provider profile · identity verified
Nathaniel P Fleischner, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ROYAL PALM BEACH, FL · NPI 1083880926
Verified facts
What the public records show
CMS Open Payments records show Nathaniel P Fleischner, M.D. received $183.58 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.62 | 26.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.92 | 25.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.31 | 15.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.70 | 12.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.56 | 10.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.47 | 9.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $183.58 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $43.93 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.31 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 66 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 416 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 327 | 114 |
| Losartan Potassium | Losartan Potassium | 279 | 98 |
| Metformin Hcl | Metformin Hcl | 229 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 222 | 68 |
| Lisinopril | Lisinopril | 196 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 61 |
| Alprazolam | Alprazolam | 168 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 152 | 46 |
| Omeprazole | Omeprazole | 144 | 50 |
| Gabapentin | Gabapentin | 140 | 59 |
| Carvedilol | Carvedilol | 138 | 47 |
| Nifedipine Er | Nifedipine | 123 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 44 |
| Tramadol Hcl | Tramadol Hcl | 112 | 25 |
| Temazepam | Temazepam | 104 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 37 |
| Eliquis | Apixaban | 96 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 49 |
| Ezetimibe | Ezetimibe | 92 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 28 |
| Furosemide | Furosemide | 83 | 29 |
| Simvastatin | Simvastatin | 83 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 46 |
| Methylprednisolone | Methylprednisolone | 79 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 25 |
| Alendronate Sodium | Alendronate Sodium | 68 | 25 |
| Jardiance | Empagliflozin | 66 | 20 |
| Trazodone Hcl | Trazodone Hcl | 66 | 18 |
| Clonazepam | Clonazepam | 65 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 26 |
| Sertraline Hcl | Sertraline Hcl | 59 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 19 |
| Meloxicam | Meloxicam | 58 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 25 |
| Famotidine | Famotidine | 54 | 26 |
| Bumetanide | Bumetanide | 52 | 22 |
| Montelukast Sodium | Montelukast Sodium | 52 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 34 |
| Donepezil Hcl | Donepezil Hcl | 48 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 14 |
| Glipizide | Glipizide | 47 | 22 |
| Ozempic | Semaglutide | 47 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 46 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 45 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 25 |
| Allopurinol | Allopurinol | 40 | 11 |
| Azelastine Hcl | Azelastine Hcl | 40 | 30 |
| Buspirone Hcl | Buspirone Hcl | 39 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 15 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Valsartan | Valsartan | 39 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Irbesartan | Irbesartan | 37 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 15 |
| Potassium Chloride | Potassium Chloride | 37 | 18 |
| Finasteride | Finasteride | 35 | 11 |
| Ketoconazole | Ketoconazole | 35 | 18 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 34 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 12 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Prednisone | Prednisone | 33 | 23 |
| Sildenafil Citrate | Sildenafil Citrate | 33 | 12 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 14 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Acarbose | Acarbose | 30 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 11 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 20 |
| Diazepam | Diazepam | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 21 |
| Bupropion Xl | Bupropion Hcl | 26 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Lactulose | Lactulose | 25 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 13 |
| Naproxen | Naproxen | 24 | 17 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 16 |
| Ciclopirox | Ciclopirox | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 14 | 11 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Klor-Con M15 | Potassium Chloride | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Ramipril | Ramipril | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $183.58 · 9 records | Novo Nordisk Inc | Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, Ozempic, Rybelsus, TRELEGY ELLIPTA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error